We are engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Controlled-release means releasing a drug into the bloodstream or at a target site in the body, over an extended period of time or at predetermined times. In some circumstances, controlled-release drug delivery can enhance efficacy and patient compliance as compared to immediate release formats for the same drug.

Our proprietary Hypermatrix™ technology is at the core of our controlled-release drug delivery approach. The flexibility of the Hypermatrix™ technology allows for the intelligent and efficient design of drugs through the precise control of a number of key variables. This allows us to respond to varying drug attributes and patient requirements, producing a desired controlled-release effect in a time and cost-effective manner.

We are applying our technology to the development of both existing and new pharmaceuticals across a range of therapeutic classes. The flexibility and the competitive advantage of the Hypermatrix™ technology allow us to focus our development activities in two niche markets:


  1. Difficult-to-produce controlled-release generic drugs (ANDA regulatory path)
  2. Improved current therapies through controlled-release (NDA regulatory path)
Our ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, pain. Our lead product, a generic of Focalin XR®, is partnered with Par Pharmaceutical, Inc. and recently received FDA approval on the 15 and 30mg strength, and tentative approval on the 5,10,20 and 40mg strength. We are also developing our Rexista ® technology, an innovative new drug designed to overcome the well documented abuses associated with oxycodone and other opioid analgesics.

Our management and scientific teams have a history of successfully developing and bringing prescription controlled-release drugs to market. We are passionate about our business.